Cochlear has developed an implantable medical device system that automates the delivery of treatment substances to the inner ear. It utilizes in-vivo biomarkers and electrophysiological measurements to assess biological states, enabling precise control and regulation of treatment based on detected changes in hair cells or synapses. GlobalData’s report on Cochlear gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cochlear, Neuromodulation implants was a key innovation area identified from patents. Cochlear's grant share as of July 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Automated treatment delivery system for inner ear implants
The granted patent US12070575B2 describes an innovative implantable medical device system designed for use in the inner ear of recipients. This system comprises a sensor, an implantable reservoir for treatment substances, and a processor that collectively facilitate the monitoring and treatment of auditory or vestibular conditions. The sensor is capable of capturing electrophysiological measurements, such as electrically evoked compound action potentials (ECAP) or electrocochleography (ECoG), which are critical for assessing the health of hair cells and synapses in the inner ear. The processor utilizes these measurements to control the delivery of treatment substances from the reservoir, ensuring that the dosage is auto-regulated based on real-time feedback from the sensor. Additionally, the system includes a stimulating assembly that can deliver electrical or acoustic stimuli to evoke neural responses, further enhancing its therapeutic capabilities.
The patent also outlines methods for utilizing the device, including the delivery of electrical or acoustic stimuli followed by the capture of electrophysiological measurements during a fixed duration sample window. These measurements inform the control output for the treatment substance delivery, allowing for precise modulation based on the recipient's physiological responses. The system is designed to detect changes in auditory or vestibular nerve function and can adjust treatment accordingly, including the administration of substances to maintain homeostasis in response to cellular changes. Overall, this patent presents a comprehensive approach to managing inner ear conditions through a combination of real-time monitoring and targeted treatment delivery, potentially improving outcomes for individuals with auditory or vestibular impairments.
To know more about GlobalData’s detailed insights on Cochlear, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
